Lupron Depot (Leuprolide Injection (Prostate)) and Bone mineral density
Result of checking the interaction of drug Lupron Depot (Leuprolide Injection (Prostate)) and disease Bone mineral density for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide. It can be anticipated that long periods of medical castration in men will have effects on bone density. Bone density loss may not be reversible. Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids). Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.
- "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.
Generic Name: leuprolide
Brand Name: Eligard, Lupron Depot, Lupron, Lupron Depot-Ped, Lupron Depot-Gyn, Viadur
Synonyms: Leuprolide